Recent advances in triple negative breast cancer: the immunotherapy era
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in triple negative breast cancer: the immunotherapy era
Authors
Keywords
-
Journal
BMC Medicine
Volume 17, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-09
DOI
10.1186/s12916-019-1326-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancing anti-tumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
- (2019) K M Heinhuis et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here
- (2018) Maryann J. Kwa et al. CANCER
- Abstract PD6-03: Distribution of microsatellite instability, tumor mutational load, and PD-L1 status in molecularly profiled invasive breast cancer
- (2018) E Obeid et al. CANCER RESEARCH
- Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
- (2018) SM Tolaney et al. CANCER RESEARCH
- Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
- (2018) Peter Savas et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.
- (2018) Shaveta Vinayak et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
- (2018) Alexandra Thomas et al. OncoImmunology
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
- (2017) Reinhard Büttner et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
- (2017) Emma Nolan et al. Science Translational Medicine
- A molecular portrait of microsatellite instability across multiple cancers
- (2017) Isidro Cortes-Ciriano et al. Nature Communications
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
- (2017) Carlos R. Gil Del Alcazar et al. Cancer Discovery
- DNA Damage and Repair Biomarkers of Immunotherapy Response
- (2017) Kent W. Mouw et al. Cancer Discovery
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer
- (2016) Carmen Criscitiello et al. CANCER TREATMENT REVIEWS
- Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
- (2016) Rhiannon K Beckers et al. HISTOPATHOLOGY
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- What does PD-L1 positive or negative mean?
- (2016) Antoni Ribas et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis
- (2016) Xue Li et al. Targeted Oncology
- Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
- (2015) M. V. Dieci et al. ANNALS OF ONCOLOGY
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model
- (2015) Xiang Huang et al. IMMUNOLOGIC RESEARCH
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Natural and therapy-induced immunosurveillance in breast cancer
- (2015) Guido Kroemer et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
- (2015) Jonathan Pol et al. OncoImmunology
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer
- (2013) Y. Homma et al. Clinical & Translational Oncology
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Effects of conventional therapeutic interventions on the number and function of regulatory T cells
- (2013) Mario Roselli et al. OncoImmunology
- Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo
- (2012) Connie Jackaman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now